ITPase Activity Modulates the Severity of Anaemia in HCV-Related Cirrhosis Treated with Ribavirin-Containing Interferon-Free Regimens

Abstract

Background

To investigate the association between inosine triphosphatase (ITPase) activity and the degree of anaemia occurring during direct-acting antiviral (DAA)/ribavirin (RBV)-based therapy in patients with cirrhosis.

Methods

In a multicentre, prospective study 227 patients with HCV-related cirrhosis treated with DAA and RBV were enrolled. All patients were screened for the rs1127354 and rs7270101 ITPA single nucleotide polymorphisms using direct sequencing.

Results

150 (66.1%) patients had normal (100%) ITPase activity, 48 (21.1%) had moderate (60%) activity and 29 (12.8%) minimal (≤30%) activity. The ITPase activity significantly influenced the haemoglobin concentration: at day 15 it was -1.248 (sd ±0.978) in the 150 patients with an ITPase activity of 100% and -0.616 (±0.862) in the 77 patients with an ITPase activity less than 100% (P <0.000), and at day 30 it was -1.941 ±1.218 versus -1.11 ±1.218 (P <0.000). The 63 patients with a severe (at least 3/dl) haemoglobin decline, compared to those without, more frequently had an ITPase activity of 100% (82.1% versus 62.8%; P=0.021), were older (mean age ±sd: 66.7 ±8.2 versus 61.4 ±9.7 years; P=0.004) and were treated with a higher ribavirin dose (13.7 ±2.1 versus 12.8 ±2.5 mg/ kg/day; P=0.008). At multivariate logistic regression analysis, the ITPase activity of 100% (OR: 2.83; 95% CI: 1.12, 7.10), male gender (OR: 3.22; 95% CI: 1.35, 7.66), body mass index (OR: 1.17; 95% CI: 1.03, 1.34) and dose of ribavirin (OR: 1.22; 95% CI: 1.06, 1.47) were independent predictors of a severe decline in haemoglobin (P<0.0001).

Conclusions

This study suggests that the polymorphisms in the ITPA gene influence the severity of anaemia during the first month of a DAA/RBV-based treatment in HCV-related cirrhosis.

References

Gower

, Estes

, Blach

, Razavi-Shearer

, Razavi

Global epidemiology and genotype distribution of the hepatitis C virus infection.

J Hepatol 2014; 61 Suppl 1: S45–S57.

Coppola

, Zampino

, Bellini

Association between a polymorphism in cannabinoid receptor 2 and severe necroinflammation in patients with chronic hepatitis C.

Clin Gastroenterol Hepatol 2014; 12: 334–340.

Coppola

, Pisapia

, Tonziello

Virological pattern in plasma, peripheral blood mononuclear cells and liver tissue and clinical outcome in chronic hepatitis B and C virus coinfection.

Antivir Ther 2008; 13: 307–318.

Miller

M.H.

, Agarwal

, Austin

Review article: 2014 UK consensus guidelines–hepatitis C management and direct-acting anti-viral therapy.

Aliment Pharmacol Ther 2014; 39: 1363–1375.

Vezali

, Aghemo

, Colombo

A review of the treatment of chronic hepatitis C virus infection in cirrhosis.

ClinTher 2010; 32: 2117–2138.

Borgia

, Reynaud

, Gentile

Pernicious anemia during IFN-alpha treatment for chronic hepatitis C.

J Interferon Cytokine Res 2003; 23: 11–12.

European Association for Study of Liver.

EASL Recommendations on Treatment of Hepatitis C 2015.

J Hepatol 2015; 63: 199–236.

McHutchison

J.G.

, Manns

, Patel

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

Gastroenterology 2002; 123: 1061–1069.

Fellay

, Thompson

A.J.

, Ge

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

Nature 2010; 464: 405–408.

10.

Di Marco

, Calvaruso

, Grimaudo

Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of peg-interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices.

J Viral Hepat 2013; 20: 113–121.

11.

Scherzer

T.M.

, Stättermayer

A.F.

, Stauber

Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients.

J Hepatol 2013; 59: 964–971.

12.

D'Avolio

, De Nicolò

, Cusato

Association of ITPA polymorphismsr s6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients.

Antiviral Res 2013; 100: 114–119.

13.

Clark

P.J.

, Aghemo

, Degasperi

Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy.

J Viral Hepat 2013; 20: 858–866.

14.

Chayama

, Hayes

C.N.

, Abe

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C.

J Infect Dis 2011; 204: 84–93.

15.

Suzuki

, Suzuki

, Akuta

Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.

Hepatology 2011; 53: 415–421.

16.

Coppola

, Zampino

, Cirillo

TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism.

Liver Int 2015; 35: 1959–1963.

17.

Zampino

, Pisaturo

M.A.

, Cirillo

Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration.

Ann Hepatol 2015; 14: 75–82.

18.

Coppola

, Gentile

, Pasquale

Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C.

Ann Hepatol 2013; 13: 20–26.

19.

European Association for the Study of the Liver.

EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

J Hepatol 2011; 55: 245–264.

20.

Filippini

, Coppola

, Pisapia

Virological and clinical aspects of HBV-HCV coinfection in HIV positive patients.

J Med Virol 2007; 79: 1679–1685.

21.

Zampino

, Alessio

, Marrone

Role of ITPA and IL28B variants in the management of chronic hepatitis C treatment.

Infez Med 2015; 23: 134–139.

22.

Stickel

, Helbling

, Heim

Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C.

J Viral Hepat 2012; 19: 77–87.

23.

Piccinino

, Coppola

Antiviral treatment of HCV-related cirrhosis.

Dig Liver Dis 2007; 39 Suppl 1: S96–S101.

24.

Coppola

, Pisaturo

, Sagnelli

, Angelillo

I.F.

Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors.

PLoS One 2014; 9: e94542.

25.

Cheung

M.C.

, Walker

A.J.

, Hudson

B.E.

Outcomes after successful direct acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.

J Hepatol 2016; pii: S0168-8278(16)30314-2.

26.

Younossi

Z.M.

, Stepanova

, Henry

Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens.

Medicine (Baltimore) 2016; 95: e4151.

27.

De Franceschi

, Fattovich

, Turrini

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage.

Hepatology 2000; 31: 997–1004.

28.

Sumi

, Marinaki

A.M.

, Arenas

Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency.

Hum Genet 2002; 111: 360–367.

29.

Arenas

, Duley

, Sumi

, Sanderson

, Marinaki

The ITPA c.94C>A and g.IVS2+21A>C sequence variants contribute to missplicing of the ITPA gene.

Biochim Biophys Acta 2007; 1772: 96–102.

30.

Hitomi

, Cirulli

E.T.

, Fellay

Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function.

Gastroenterology 2011; 140: 1314–1321.

31.

Jimmerson

L.C.

, Urban

T.J.

, Truesdale

Variant ITPA phenotypes are associated with increased ribavirin triphosphate levels.

J Clin Pharmacol 2016; 57: 118–124.

32.

Thompson

A.J.

, Santoro

, Piazzolla

Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.

Hepatology 2011; 53: 389–395.

33.

Thompson

A.J.

, Fellay

, Patel

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.

Gastroenterology 2010; 139: 1181–1189.

34.

Ochi

, Maekawa

, Abe

ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy–a genome-wide study of Japanese HCV virus patients.

Gastroenterology 2010; 139: 1190–1197.

35.

Kurosaki

, Tanaka

, Nishida

Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.

J Med Virol 2013; 85: 449–458.

36.

Aghemo

, Grassi

, Rumi

M.G.

Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving telaprevir.

PLoS One 2014; 9: e95881.

37.

Ampuero

, Del Campo

J.A.

, Rojas

Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment.

J Clin Virol 2015; 68: 56–60.

38.

Morio

, Imamura

, Kawakami

Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C.

Hepatol Res 2016; 46: 1256–1263.

39.

AASLD/IDSA HCV Guidance Panel.

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.

Hepatology 2015; 62: 932–954.

40.

Ogawa

, Furusyo

, Nomura

Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis.

Antiviral Res 2016; 136: 37–44.

41.

Morio

, Imamura

, Kawakami

ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.

J Gastroenterol 2017; 52: 746–753.

42.

Ampuero

, Romero-Gómez

Pharmacogenetics of ribavirin-induced anemia in hepatitis C.

Pharmacogenomics 2016; 17: 1587–1594.